TriSalus Life Sciences
TLSI
48 hedge funds and large institutions have $46.8M invested in TriSalus Life Sciences in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 17 increasing their positions, 2 reducing their positions, and 8 closing their positions.
750% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 2
176% more capital invested
Capital invested by funds: $16.9M → $46.8M (+$29.9M)
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
33% more funds holding
Funds holding: 36 → 48 (+12)
12.64% more ownership
Funds ownership: 10.06% → 22.7% (+13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$10.7M |
| 2 |
AIC
AWM Investment Company
New York
|
+$6.71M |
| 3 |
BlackRock
New York
|
+$3.17M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.99M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$553K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$147K |
| 3 |
Renaissance Technologies
New York
|
-$112K |
| 4 |
Goldman Sachs
New York
|
-$91.6K |
| 5 |
Lido Advisors
Los Angeles,
California
|
-$78.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Lido Advisors
Los Angeles,
California
| – | -$78.4K | -14,197 | Closed |
|
|
HF
52
HRT Financial
New York
| – | -$75K | -13,657 | Closed |
|
53
Balyasny Asset Management
Chicago,
Illinois
| – | -$59.6K | -10,804 | Closed |
|
|
TSS
54
Two Sigma Securities
New York
| – | -$58.5K | -10,596 | Closed |
|
55
Prudential Financial
Newark,
New Jersey
| – | -$55.2K | -10,000 | Closed |
|
|
CCM
56
Coldstream Capital Management
Bellevue,
Washington
| – | -$828 | -150 | Closed |
|
TLSI Hedge Fund Activity: Q2 2025 in Review
48 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q2 2025, worth a combined $46.8M — up 176% from $16.9M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TLSI positions and 8 closed out — a net gain of 12 holders — while 17 added to existing stakes and 2 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $10.7M. The largest seller was Millennium Management, cutting an estimated $553K.
- 48 institutional investors held TriSalus Life Sciences (TLSI) as of Q2 2025, up from 36 in Q1 2025.
- Funds reported $46.8M of TriSalus Life Sciences stock for Q2 2025, up 176% quarter-over-quarter.
- 20 funds opened new TriSalus Life Sciences positions in Q2 2025 and 8 closed out, a net change of +12 holders.
- The largest TriSalus Life Sciences buyer in Q2 2025 was Nantahala Capital Management, an estimated $10.7M added.
- The largest TriSalus Life Sciences seller in Q2 2025 was Millennium Management, an estimated $553K sold.
Based on aggregated 13F filings for Q2 2025.